Episurf Medical AB (STO:EPISB), a provider of minimally invasive and personalised treatment alternatives for people with painful joint injuries, announced on Friday that it has CE-marked a new knee joint visualisation tool, which will be released to the European market following a controlled launch process.
This tool, named Epioscopy, is a web-based application based on artificial intelligence (AI), providing an overview of a knee joint's clinical condition.
According to the company, Epioscopy is intended to assist healthcare professionals in their planning of optimal treatments for patients' knees by interactive 3D visualisation of structures and possible structural deviations.
Episurf Medical offers the Episealer personalised implants and Epiguide surgical drill guides, which are developed for treating localised cartilage injury in joints. Episurf Medical's µiFidelity system enables implants to be cost-efficiently tailored to each individual's unique injury for the optimal fit and minimal intervention.
Nuevocor names new chief medical officer
ELIAS Animal Health names new chief revenue officer
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
HealthTrackRx names new chief medical officer
PureTech announces launch of Seaport Therapeutics with USD100m Series A financing
REVIAN names new vice president of Healthcare Sales
Orsini Specialty Pharmacy names new CFO and EVP of Trade Relations and Account Management
Ligand Pharmaceuticals launches Pelthos Therapeutics to drive ZELSUVMI commercialisation
Soligenix announces agreement on design for second Phase 3 trial for HyBryte with EMA
Ratio Therapeutics names new chief business officer and director
Trevi Therapeutics names new vice president of Clinical Development
NeoImmuneTech names new president and chief executive officer